US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
Vous pourriez aussi aimer
À la hausse
Dernières actus crypto
Trump déclare que le président de la Fed devrait réduire les taux d'intérêt et réitère ses critiques contre Powell
Au cours des dernières 24 heures, l'ensemble du réseau a liquidé 376 millions de dollars, la majorité provenant de la plus grande position vendeuse
La probabilité d'une baisse des taux d'intérêt de 25 points de base par la Réserve fédérale en décembre est actuellement de 87,2%.
Trump: Annoncera le nouveau président de la Fed au début de l'année prochaine
Le site international Coinbase lancera le trading à contrat perpétuel DASH
Assistance client:@weikecs
Collaborations commerciales:@weikecs
Trading quantitatif/Market makers:[email protected]
Programme VIP:[email protected]